Transcenta Holding Limited (HKG:6628)
2.550
+0.390 (18.06%)
At close: Mar 27, 2026
Transcenta Holding Revenue
Transcenta Holding had revenue of 2.71M CNY in the half year ending June 30, 2025, a decrease of -92.49%. This brings the company's revenue in the last twelve months to 9.41M, down -57.87% year-over-year. In the year 2024, Transcenta Holding had annual revenue of 11.26M, down -79.09%.
Revenue (ttm)
9.41M CNY
Revenue Growth
-57.87%
P/S Ratio
111.28
Revenue / Employee
55.02K CNY
Employees
171
Market Cap
1.15B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.26M | -42.59M | -79.09% |
| Dec 31, 2023 | 53.85M | -48.04M | -47.15% |
| Dec 31, 2022 | 101.89M | 51.65M | 102.80% |
| Dec 31, 2021 | 50.24M | -30.74M | -37.96% |
| Dec 31, 2020 | 80.98M | 36.84M | 83.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 491.34M |
| Cutia Therapeutics | 374.07M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Brii Biosciences | 39.56M |
| Zhaoke Ophthalmology | 35.58M |
Transcenta Holding News
- 3 months ago - Transcenta Collaborates With EirGenix To License HiCB Platform - Nasdaq